Patents Examined by Rebecca L. Anderson
  • Patent number: 11834431
    Abstract: A crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having peaks at diffraction angles 2?)(° of 12.6±0.2, 16.0±0.2, 17.7±0.2, 18.5±0.2, and 21.3±0.2 in powder X-ray diffraction; and the crystal of ethane disulfonate of (S)-1-(4-(dimethylamino)piperi din-1-yl)-3-hydroxy-3-(1-methyl-1H-imidazol-2-yl)propan-1-one, having an endothermic peak at 173° C. to 177° C. in simultaneous thermogravimetric-differential thermal analysis.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: December 5, 2023
    Assignee: Toray Industries, Inc.
    Inventors: Hirozumi Takahashi, Yoko Baba, Yasuhiro Morita, Katsuhiko Iseki, Naoki Izumimoto
  • Patent number: 11827619
    Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
    Type: Grant
    Filed: May 10, 2023
    Date of Patent: November 28, 2023
    Assignee: INIPHARM, INC.
    Inventors: Sampath Kumar Anandan, Joshua Odingo, Heather Kay Webb Hsu, Vincent Florio, Subramanyam Janardhan Tantry, Athisayamani Jeyaraj Duraiswamy
  • Patent number: 11827602
    Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: November 28, 2023
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 11820779
    Abstract: Novel tetracyclic aza-podophyllotoxin analogue compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The tetracyclic aza-podophyllotoxin analogue compounds are useful as antitumor agents.
    Type: Grant
    Filed: March 15, 2023
    Date of Patent: November 21, 2023
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11802111
    Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: October 31, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jesus Alcazar, Michael K. Ameriks, Cynthia B. Berry, Pablo Garcia-Reynaga, Brian Ngo Laforteza, Andrew V. Samant
  • Patent number: 11795174
    Abstract: Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 24, 2023
    Inventors: Runtao Li, Jia Ye, Xin Wang, Zemei Ge, Yingying Liang, Xiaolei Du, Ding Wang, Guimin Zhang, Jingchun Yao, Guifang Zhao
  • Patent number: 11795160
    Abstract: A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: October 24, 2023
    Assignee: Insilico Medicine IP Limited
    Inventors: Aleksandr Aliper, Vladimir Aladinskiy, Aleksandrs Zavoronkovs
  • Patent number: 11795147
    Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: October 24, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kai Gerlach, Christian Eickmeier, Jan Magnus Kriegl, Lothar Kussmaul, Klaus Rudolf, Bernhard Schmid
  • Patent number: 11787814
    Abstract: Disclosed is a method for preparing 2-indolinospirone compound and intermediate thereof, specifically disclosed is a method for preparing a compound of formula 5. The method is relatively simple and has high stereoselectivity and yield.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: October 17, 2023
    Assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
    Inventors: Ming Guo, Jianfeng Wen, Jianpeng Feng, Tianzhu Wu, Huirong Lu
  • Patent number: 11780849
    Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: October 10, 2023
    Assignee: Volastra Therapeutics, Inc.
    Inventors: Derek A. Cogan, Sarah Bettigole, Leon Van Berkom, Piotr Nieczypor, Michael Su, Rutger Folmer
  • Patent number: 11773063
    Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: October 3, 2023
    Assignee: Beckley Psytech Limited
    Inventors: Jason Gray, Susana Del Rio Gancedo, Dita Davis, David James Pearson, Daniel Rixson
  • Patent number: 11767293
    Abstract: The various aspects present inventions provide various crystalline forms of (S)-(?)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: September 26, 2023
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
  • Patent number: 11760730
    Abstract: An improved process for the preparation of high purity Levosimendan includes treatment of Levosimendan crude with an organic acid, adding an organic acid to precipitate Levosimendan and isolating pure Levosimendan from the precipitate. Levosimendan obtained by the improved process is pharmaceutically acceptable with no impurity higher than 0.2 percent.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: September 19, 2023
    Assignee: Navinta, LLC
    Inventors: Chiragkumar Anilkumar Bhatt, Keyurkumar Amrutla Pandya, Pankaj Vasudev Parmar, John Muthiah Raja Jeyakumar
  • Patent number: 11760741
    Abstract: The present invention is directed to pro-drugs of Eliglustat (formula A) and process for the preparation thereof. The present invention is further directed to pharmaceutical composition thereof and method of treatment using the same.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 19, 2023
    Inventors: Parva Yogeshchandra Purohit, Pathik Subhashchandra Brahmkshatriya
  • Patent number: 11739072
    Abstract: The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: August 29, 2023
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Xavier Barril Alonso, Elena Cubero Jordà, Marc Revés Vilaplana, Richard Spurring Roberts
  • Patent number: 11739100
    Abstract: The invention relates to the novel products of formula (I): with p, q=0, 1 or 2; R1=phenyl, pyridyl; —(CH2)m—Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; —SO2—Rb; —CO—Re; m=1 or 2; Ra=aryl, heteroaryl, —CO-cycloalkyl, —CO-heterocycloalkyl, —CO—Rb, —C(Rb)?N—ORc, —CO2Rd, —CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is and the isomer of configuration R,R these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 29, 2023
    Assignee: SANOFI
    Inventors: Youssef El-Ahmad, Bruno Filoche-Romme, Jean-Philippe Letallec, Gilbert Marciniak, Baptiste Ronan, Bertrand Vivet, Maurice Brollo
  • Patent number: 11739082
    Abstract: The present invention relates to novel thiophene compounds of general Formula I, and their stereoisomers (diastereoisomers, enantiomers), pure or mixed, racemic mixtures, geometrical isomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, solid forms and mixtures thereof along with process for their preparation. The present invention discloses compounds that are useful in the treatment and prevention of autoimmune diseases.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 29, 2023
    Assignee: Ahammune Biosciences Private Limited
    Inventors: Kashinath Komirishetty, Mahesh Kumar Verma, Parul Ganju, Sudhanand Prasad
  • Patent number: 11739057
    Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: August 29, 2023
    Inventors: Sridhar Reddy Male, Saurabh Upadhyay, Suneel Kumar Sharma, Hrishikesh Acharya, Govind Singh, Saswata Lahiri, Walter Cabri
  • Patent number: 11731967
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of TRIM33, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which TRIM33 plays a role.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 22, 2023
    Inventors: Jun Qi, Cheng-kui Pei
  • Patent number: 11731980
    Abstract: The furo[3,4-b]quinolone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: August 22, 2023
    Inventors: Christophe Tratrat, Michelyne Haroun